Folate Receptor-Targeted TLR7a
Toll-Like Receptor 7 (TLR7) is a promising oncology target that induces a robust immune response when activated. Morphimmune's folate receptor targeted TLR7 agonist (FA-TLR7a) takes a unique approach, delivering its potent, proprietary payload directly to immunosuppressive cells in the tumor microenvironment. The result is a drug with monotherapy promise and the potential for synergistic combination therapy when combined with checkpoint inhibitors.
Morphimmune is advancing a Fibroblast Activation Protein (FAP) targeted radioligand therapy with multi-indication potential. FAP is expressed in over 75% of solid tumors including lung, breast, and esophageal cancer. MorphImmune's preclinical candidates build on work Low Lab at Purdue, which also patented key components of Pluvicto™.